Merck, known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for suvorexant, Merck’s investigational medicine for the treatment of insomnia.
http://www.news-medical.net/news/20130702/Merck-receives-Complete-Response-Letter-for-suvorexant-from-FDA-for-treatment-of-insomnia.aspx